This results in significant suppression of tumor growth and metastasis, as well as enhanced sensitivity to immune checkpoint therapy and EGFR antibodies.[11c] In another study, conditional elimination of KRAS G12D or the use of a KRAS G12D inhibitor led to an enhancement of major histocompatibility complex (MHC) II antigen presentation signaling, resulting in increased infiltration and activation of antigen‐presenting cells, CD4+ T cells, and CD8+ T cells. This evidence concerns the gene KRAS and neoplasm.